Brief: Better Therapeutics Completes Pivotal Trial Of BT-001 For Type 2 Diabetes

Better Therapeutics

28/07/2022 12:34

July 28 (Reuters) - Better Therapeutics Inc  BTTX.O :
    * BETTER THERAPEUTICS COMPLETES PIVOTAL TRIAL OF BT-001 FOR
TYPE 2
DIABETES AND ANNOUNCES POSITIVE SECONDARY ENDPOINT RESULTS
FOLLOWING THE EARLIER ANNOUNCEMENT OF POSITIVE PRIMARY ENDPOINT
RESULTS
    * BETTER THERAPEUTICS INC - DATA DEMONSTRATES BT-001 WAS
DURABLE
WITH A1C REDUCTIONS CONTINUING TO IMPROVE AFTER 180 DAYS OF
TREATMENT
    * BETTER THERAPEUTICS INC - ON TRACK TO SUBMIT A DE NOVO
CLASSIFICATION REQUEST WITH FDA FOR BT-001 IN Q3 OF 2022

Source text for Eikon:  ID:nBwc7vQ2ga 
Further company coverage:  BTTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))